Thrombotic microangiopathy in systemic lupus erythematosus: Efficacy of eculizumab

American Journal of Kidney Diseases

Volumn 65, Issue 1, 2015, Pages 127-130

  El Husseini, Amr ^a,b   Hannan, Schot ^a   Awad, Ahmed ^a   Jennings, Stuart ^a   Cornea, Virgilius ^a   Sawaya, B Peter ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Acute kidney injury (AKI); Atypical hemolytic uremic syndrome (aHUS); Eculizumab; Kidney biopsy; Lupus nephritis; Proteinuria; Systemic lupus erythematosus (SLE); Thrombotic microangiopathy (TMA)

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; ECULIZUMAB; HEMOGLOBIN; MENINGOCOCCUS VACCINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN V; PREDNISONE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ANALYTICAL PARAMETERS; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CASE REPORT; CHRONOTHERAPY; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LUNG EDEMA; LUPUS ERYTHEMATOSUS NEPHRITIS; PLASMAPHERESIS; PROTEIN CREATININE RATIO; REMISSION; RESPIRATORY FAILURE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT; ACUTE KIDNEY INJURY; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BIOPSY; COMPLICATION; DRUG EFFECTS; DRUG MONITORING; GLOMERULUS FILTRATION RATE; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BIOPSY; DRUG MONITORING; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; REMISSION INDUCTION; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922373286     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.07.031     Document Type: Article

References (21)

1. Gharbi C, Bourry E, Rouvier P, et al. Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy. Clin Exp Nephrol. 2010; 14 (5): 487-491
2. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355 (12): 1233-1243
3. Caprioli J, Noris M, Brioschi S, et al; International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006; 108 (4): 1267-1279
4. Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov. 2010; 1: 43-56
5. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347: 589-600
6. Veyradier A, Meyer D. Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost. 2005; 3: 2420-2427
7. Schmidtko J, Peine S, El-Housseini Y, et al. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: A focus on eculizumab. Am J Kidney Dis. 2013; 61 (2): 289-299
8. Hunt BJ, Tueger S, Pattison J, et al. Microangiopathic haemolytic anaemia secondary to lupus nephritis: An important differential diagnosis of thrombotic thrombocytopenic purpura. Lupus. 2007; 16: 358-362
9. Vaidya S, Abul-ezz S, Lipsmeyer E. Thrombotic thrombocytopenic purpura and systemic lupus erythematosis. Scand J Rheumatol. 2001; 30: 308-310
10. Gatenby PA, Smith H, Kirwan P, et al. Systemic lupus erythematous and thrombotic thrombocytopenic purpura: A case report and review of relationship. J Rheumatol. 1981; 8: 504-508
11. Blake JS, Butani L. Rapidly progressive lupus glomerulonephritis and concomitant microangiopathy in an adolescent. Lupus. 2002; 11: 533-535
12. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368: 2169-2181
13. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011; 11 (11): 2523-2527
14. Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol. 2013; 148 (3): 313-321
15. Furie R, Matis L, Rollins S, et al. A single dose, placebocontrolled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with systemic lupus erythematosus. Innovative Therapies in Autoimmune Diseases. Abstract presented at: American College of Rheumatology 68th Annual Scientific Meeting, October 19, 2004, San Antonio, TX
16. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010; 362: 1744-1745
17. Shapira I, Andrade D, Allen SL, et al. Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012; 64: 2719-2723
18. Mushin SA, Khianey R, Erkan D. Comment: Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother. 2013; 47 (9): 1239-1240
19. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014; 13 (6): 685-696
20. Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 360: 542-544
21. Sinibaldi S, Guzzo I, Piras R, et al. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant. 2013; 17 (8): E177-E181.